CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 27 enrolled
Drug / intervention
human insulin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00065130
NCT00065130Phase 3Completed
CompareCT.gov

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Basal/Bolus Therapy for Patients With Gestational Diabetes

Novo Nordisk A/S·interventional·Posted Jul 18, 2003·Updated Dec 22, 2016

In Brief

A Phase 3 clinical trial evaluating human insulin, insulin NPH, and 1 other intervention for Diabetes and Gestational Diabetes. Completed, enrolled 27 participants across 1 site.

Detailed Summary

This trial is conducted in the United States of America (USA). The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose after meals in women who develop diabetes during pregnancy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Gestational Diabetes
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 18, 2003
Enrollment StartApr 1, 2000
Primary CompletionDec 1, 2003
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 23.0 years ago

Interventions

human insulindrug

insulin NPHdrug

insulin aspartdrug